Opinion

Video

Preoperative Monitoring and Surgical Options for HER2+ Patients

Author(s):

Joyce O'Shaughnessy, MDMelinda L. Telli, MD

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

Video content above is prompted by the following question(s):

  • How do you monitor patients during preoperative therapy for HER2+ disease regarding discussions around surgical options that the patient has?
Related Videos
Video 4 - 2 KOLs are featured in, "Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC"
Video 2 - 2 KOLs are featured in, "Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway"
4 KOLs are featured in this series
4 KOLs are featured in this series
Paolo Tarantino, MD
Andrew Davis, MD
4 KOLs are featured in this series
4 KOLs are featured in this series
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
Related Content
FDA
July 3rd 2024

OncLive’s June Roundup of Key FDA Approvals in Oncology

Martin F. Dietrich, MD, PhD, medical oncologist, Cancer Care Centers of Brevard, The US Oncology Network, assistant professor, internal medicine, the University of Central Florida College of Medicine; Michelle Shiller, DO, cancer liaison physician, medical director, Genetics, assistant medical director, Baylor Scott & White Health in Dallas, medical director, Genomics and Molecular Pathology Services, PathGroup
June 27th 2024

Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

Kevin Kalinsky, MD, MS, professor, medical oncology division director, Department of Hematology and Medical Oncology, Emory University School of Medicine; director, Glenn Family Breast Center, Emory Winship Cancer Institute; member, Discovery and Developmental Therapeutics Research Program, Winship Cancer Institute of Emory University
June 29th 2024

postMONARCH Meets Primary End Point of Improvement of PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

State of the Science Summit - Breast Cancer: Chaired by Paolo Tarantino, MD, and Sara Tolaney, MD, MPH
June 27th 2024

State of the Science Summit - Breast Cancer: Chaired by Paolo Tarantino, MD, and Sara Tolaney, MD, MPH

Peter Forsyth, MD
June 26th 2024

Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer